Is CSG (ENXTAM:CSG) Undervalued Following Its Federal Ammunition Contract Win?

CSG (ENXTAM:CSG) is back in focus after group company Federal Ammunition won a long term supply contract with the Nordic Police for up to 35 million rounds of duty and training ammunition.

See our latest analysis for CSG.

Recent news on Federal Ammunition and fresh defence contracts with Poland arrive after a sharp 28.6% 1 month share price return. However, the year to date share price return is down 42.4%, which suggests short term momentum is improving while the longer term picture remains weak.

If you are looking beyond CSG and want to see what else is moving in defence related supply chains, take a look at 39 power grid technology and infrastructure stocks

After a 28.6% jump in a month yet a 42.4% decline year to date, CSG now sits at an interesting crossroads. Does that combination make buying today more appealing than waiting for a cheaper entry based on valuation?

Most Popular Narrative: 36.9% Undervalued

According to the most widely followed narrative on CSG, the fair value sits at €30 per share compared with the last close at €18.92, which points to a sizeable valuation gap that investors are watching closely.

CSG represents a high-quality industrial compounder operating in a structurally growing and geopolitically reinforced market, with strong competitive advantages, high visibility of revenues, and capable owner-operators.

Overall (Buffett-style view): A “good business at a potentially attractive price”, with durability supported by macro tailwinds rather than purely internal economics.

Read the complete narrative.

The narrative focuses on CSG turning a large defence backlog into robust cash flows. It assumes strong margins, disciplined reinvestment, and meaningful earnings compounding over time.

Result: Fair Value of €30 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this CSG narrative could be challenged if defence spending weakens or if large government contracts are delayed. This would affect backlog conversion and cash generation.

Find out about the key risks to this CSG narrative.

Next Steps

If this mix of optimism and caution around CSG leaves you unsure, act quickly and review both sides of the story for yourself with the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond CSG?

If you stop with CSG, you could miss other opportunities. Use the Simply Wall Street Screener to quickly surface fresh ideas that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com